Want to see KR:003060 full AI Analyst Report?
Top Page
Aprogen Biologics
(003060)
Select Model
Select Model
Rating:40Underperform
Price Target:
$1,318.00
Action:N/A
Date:10/28/26
The score is primarily constrained by weak financial performance: persistent heavy losses, negative gross profit, and ongoing cash burn alongside rising leverage. Technicals also weigh on the score, with the stock trading below all key moving averages and negative MACD indicating a strong downtrend. Valuation provides limited support because the negative P/E reflects unprofitable operations and no dividend yield is available.
Positive Factors
Revenue Growth
Revenue growth provides evidence that Aprogen retains some commercial traction despite severe losses. Continued top-line expansion can support operating leverage and improve the economics of its biologics portfolio if growth is sustained and eventually matched by better cost control.
Negative Factors
Severe Unprofitability
Negative gross profit and exceptionally deep operating and net margins indicate that the current business model is not covering its underlying costs. Persistent losses weaken internal funding capacity and make revenue growth less valuable until pricing, costs, or product economics improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue growth provides evidence that Aprogen retains some commercial traction despite severe losses. Continued top-line expansion can support operating leverage and improve the economics of its biologics portfolio if growth is sustained and eventually matched by better cost control.
Read all positive factors
Aprogen Biologics (003060) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩41.40B
Dividend YieldN/A
Average Volume (3M)103.69K
Price to Earnings (P/E)―
Beta (1Y)0.10
Revenue Growth26.13%
EPS Growth58.75%
CountryKR
Employees377
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding30,079,500
10 Day Avg. Volume88,108
30 Day Avg. Volume103,690
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)0.50
Price to Sales (P/S)1.41
P/FCF Ratio-2.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aprogen Biologics Business Overview & Revenue Model
Company Description
Aprogen Biologics, Inc. specializes in the production and distribution of pharmaceutical goods. The company's activities are structured across two main segments: Pharmaceutical and Bio. Its Pharmaceutical division supplies synthetic medicines, enc...
Aprogen Biologics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 86.18B | 73.23B | 67.38B | 87.36B | 65.19B | 56.48B |
| Gross Profit | -23.34B | -28.42B | -7.58B | -12.05B | 27.29B | 25.44B |
| EBITDA | -27.71B | -103.70B | -51.33B | -88.32B | 17.56B | 11.93B |
| Net Income | -78.30B | -170.33B | -104.98B | -118.27B | 5.58B | 8.10B |
Balance Sheet | ||||||
| Total Assets | 548.41B | 586.99B | 590.98B | 589.40B | 676.10B | 614.62B |
| Cash, Cash Equivalents and Short-Term Investments | 22.70B | 51.02B | 38.32B | 10.05B | 99.07B | 124.94B |
| Total Debt | 210.84B | 225.32B | 154.02B | 181.00B | 134.74B | 2.48B |
| Total Liabilities | 277.03B | 305.95B | 212.29B | 220.71B | 173.73B | 17.44B |
| Stockholders Equity | 194.24B | 207.76B | 378.49B | 368.69B | 421.72B | 507.94B |
Cash Flow | ||||||
| Free Cash Flow | -36.15B | -47.86B | -46.45B | -62.05B | 24.18B | -7.67B |
| Operating Cash Flow | -32.32B | -38.23B | -31.00B | -33.65B | 25.73B | -6.23B |
| Investing Cash Flow | -50.06B | -85.12B | -51.72B | -95.21B | -53.00B | -23.16B |
| Financing Cash Flow | 78.48B | 135.14B | 84.97B | 115.29B | 15.78B | -350.26M |
Aprogen Biologics Technical Analysis
Negative
―
Price Trends
1630.84
Negative
1888.13
Negative
3438.99
Negative
Market Momentum
-77.52
Negative
27.92
Positive
10.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:003060, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 1459.35, equal to the 50-day MA of 1630.84, and equal to the 200-day MA of 3438.99, indicating a bearish trend. The MACD of -77.52 indicates Negative momentum. The RSI at 27.92 is Positive, neither overbought nor oversold. The STOCH value of 10.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:003060.
Aprogen Biologics Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | ₩1.17T | 5.97 | ― | 0.59% | 9.87% | 160.28% | |
60 Neutral | ₩397.47B | 8.86 | ― | 1.59% | -0.65% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₩1.60T | 130.86 | ― | 0.42% | 13.88% | 29.24% | |
49 Neutral | ₩76.86B | -8.16 | ― | ― | -5.10% | 19.68% | |
46 Neutral | ₩324.15B | -55.61 | ― | 2.06% | 15.38% | ― | |
40 Underperform | ₩41.40B | -0.23 | ― | ― | 26.13% | 58.75% |
* General Sector Average
KR:003060
Aprogen Biologics
1,335.00
-6,945.00
-83.88%
KR:068760
Celltrion Pharm Inc.
36,650.00
-25,696.91
-41.22%
KR:069620
Daewoong Pharmaceutical Co., Ltd.
101,100.00
-37,819.86
-27.22%
KR:170900
Dong-A ST Co., Ltd.
33,850.00
-12,035.84
-26.23%
KR:183490
Enzychem Lifesciences Corp.
990.00
-27.00
-2.65%
KR:249420
Ildong Pharmaceutical Co., Ltd.
12,580.00
-10,764.63
-46.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.